Affimed NV (Affimed NV) Cash Flow from Financing

: $-6.71 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Affimed NV paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $1.74 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.22 Mil on other financial activities. In all, Affimed NV spent $1.52 Mil on financial activities for the three months ended in Dec. 2023.

Affimed NV Cash Flow from Financing Historical Data

The historical data trend for Affimed NV's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

28.93

84.25

150.94

93.81

-6.78

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Financing																-0.62	-0.68	-2.80	-1.72	-1.52

Affimed NV Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Affimed NV's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0.256	+	0	+	-7.001	+	0	+	0	+	-0.038
=	-6.78

Affimed NV's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-1.74	+	0	+	0	+	0.218
=	-1.52

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.71 Mil.

Affimed NV (NAS:AFMD) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Affimed NV's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Affimed NV's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Affimed NV's net issuance of debt for the three months ended in Dec. 2023 was $-1.74 Mil. Affimed NV spent $1.74 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Affimed NV's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Affimed NV paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Affimed NV's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Affimed NV received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Affimed NV's other financing for the three months ended in Dec. 2023 was $0.22 Mil. Affimed NV received $0.22 Mil on other financial activities.

Affimed NV Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Affimed NV's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.